© 2024 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Grace Halsey
Articles
Erenumab Induces Remission in Chronic Migraine Medication Overuse Headache
September 20, 2024
Erenumab 140 mg safely and effectively induced remission in nonopioid MOH within 6 months in individuals for whom other preventive medications had failed.
First-Ever CGM Cleared for 365-Day Use
September 20, 2024
The only CGM system cleared for 1 year of use in type 1 and 2 diabetes is expected to be available in the fourth quarter of this year, the manufacturers said.
Co-administration of Arexvy and Shingrix Yields Positive Topline Phase 3 Data, GSK Reports
September 19, 2024
Immune responses for both vaccines were noninferior when given at the same visit compared with separate administration among adults aged 50 years and older.
21 Beliefs about AI in Health Care, from People Like Your Patients
September 18, 2024
AI is welcomed by US adults for streamlining the administrative complexity of getting medical care but not so much for replacing health care professionals themselves.
FDA Updates Felinzanetant Label Warnings After Report of Severe Liver Injury
September 18, 2024
FDA heightened label warnings about hepatic injury and increased the required frequency of liver function testing after initiation of fezolinetant.
A False-Positive Breast Cancer Screening Result Discourages Future Mammography
September 17, 2024
Those least likely to schedule further screening mammograms had received a false-positive with recommendation for follow-up after only a short interval.
Exact Sciences Debuts Positive Topline Results for Trial of Blood-Based Colorectal Cancer Screening Algorithm
September 17, 2024
Presented at ESMO, the findings reflect “a highly discriminate blood-based panel of methylated DNA markers” as well as a robust new marker class for identifying patients with precancerous lesions.
Lilly Announces FDA Approval of Lebrikizumab-lbkz for Moderate to Severe Atopic Dermatitis
September 16, 2024
Among those treated with lebrikizumab, more than one-third saw clear/almost clear skin at week 16; three-quarters of them maintained results at week 52 with monthly dosing.
Investigational PACAP Inhibitor Reduces Monthly Migraine Days, Lundbeck Reports
September 16, 2024
Individuals with migraine who failed to respond to up to 4 previous migraine preventive treatments saw fewer monthly migraine and headache days after 1 infusion of Lu AG90222.
FDA Approves Dupilumab Label Expansion with Indication for CRSwNP in Adolescents
September 13, 2024
The approval makes dupilumab available to treat uncontrolled CRSwNP in adolescents aged 12 to 17 years, expanding on the current approved range of 18 years and older.